Form 4: Cyclo Therapeutics Director Receives Stock Grant in Lieu of Cash Compensation

C.E. Rick Strattan, a director of Cyclo Therapeutics, acquired 9,524 shares of common stock on August 16, 2024, as compensation for the second quarter of 2024.

Summary

• On August 16, 2024, C.E. Rick Strattan, a director of Cyclo Therapeutics, Inc., acquired 9,524 shares of common stock.
• The shares were received as a grant in lieu of cash compensation under the issuer's non-employee director compensation policy.
• The grant reflects director compensation for the second quarter of 2024.
• The number of shares was calculated based on a closing price of $1.26 per share on August 16, 2024.
• Following the transaction, Strattan directly owns 305,495 shares of Cyclo Therapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction related to director compensation. The director taking stock instead of cash could be seen as a slightly positive signal.

Positives

• The director's decision to take stock in lieu of cash may signal confidence in the company's future prospects.

Industry Context

Director compensation in the form of stock grants is a common practice in publicly traded companies, aligning director interests with shareholder value.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholders as it aligns director interests with the company's stock performance.

Key Dates